Kraig Biocraft Laboratories

Kraig Biocraft genetically modifies silkworms so they produce spider silk proteins directly in their cocoons, whereas most competitors express silk proteins in yeast or bacteria via fermentation and then must artificially spin those proteins into fiber. The company's in vivo approach eliminates a complex, capital-intensive post-processing step, as the silkworms naturally extrude the recombinant silk fibers. This creates a potential cost advantage if scaled reliably.

The company has held development contracts with the U.S. Army since approximately 2016 under the Dragon Silk program. These contracts funded the production and delivery of ballistic shoot packs for performance evaluation against military specifications. While collectively worth around $2 million in total funding as of 2020 (per the firm's public filings), the arrangement serves primarily as a technical validation and development pathway rather than a guaranteed procurement order.

Vietnam offers established sericulture infrastructure, a skilled agricultural workforce experienced in raising silkworms, and a cooperative regulatory environment for genetically modified organism (GMO) research and production. The company operates through a wholly owned subsidiary in Quang Nam province and has expanded its footprint there to scale production capacity as it moves toward commercialization.

The company has two primary product lines. Dragon Silk targets technical and defense textiles, particularly ballistic protection where the fiber's strength-to-weight ratio offers an advantage over incumbent materials. Monster Silk is positioned for the broader textile market, including luxury apparel and high-performance consumer goods, where the recombinant fiber's unique mechanical and aesthetic properties could command premium pricing.

Kraig Biocraft has not yet generated revenue from commercial product sales. The company has received contract payments from the U.S. Army for development work, which appear as revenue in its financial statements, but it remains pre-revenue with respect to selling silk fibers or textiles into commercial markets. It has funded operations through equity sales, warrant exercises, and convertible debt.